Literature DB >> 28853593

Changes in bone turnover markers in primary hyperparathyroidism and response to surgery.

P Rajeev1, A Movseysan2, A Baharani2.   

Abstract

Introduction Involvement of the bone is common in primary hyperparathyroidism. The aim of the study was to assess bone turnover markers in response to surgery for primary hyperparathyroidism. Methods This was a retrospective study of patients diagnosed and treated for parathyroid disease between 2005 and 2012. Interventions studied were surgery and medical treatment. The main outcome measures studied were serum levels of calcium, intact parathyroid hormone (iPTH), bone-specific alkaline phosphatase, N-terminal cross-linking propeptide of type 1 procollagen (P1NP) and C-terminal cross-linking telopeptides of type I collagen (CTX), both pre- and postoperatively at 6 months and 1 year; bone mineral density (at the spine and hip assessed by dual-energy x-ray absorptiometry after 1 year of treatment. Results A total of 122 (110 female, 12 male) patients (age range 25-91 years) underwent treatment for parathyroid disease during the study period; 30 patients were treated conservatively and 92 proceeded to surgery following localisation studies. Following surgical intervention, P1NP dropped significantly from a mean of 64.68 ng/ml (standard deviation, SD ± 68.07 ng/ml) preoperatively to 26.37 ng/ml (SD ± 20.94 ng/ml) and CTX from 0.69 pg/ml (SD ± 0.44 pg/ml) to 0.15 pg/ml (SD ± 0.16 pg/ml) at 6-12 months (P < 0.0001). This change was reflected in improvement in bone mineral density (T scores) of the hip and spine by 43% (P < 0.03) and 38% (P < 0.01), respectively, following surgery. In patients treated conservatively (n = 30), there was no improvement either in the bone turnover markers or bone densitometry scans. Conclusions Surgery improves bone density in patients with parathyroid disease. Improvement in serum bone turnover markers is seen following parathyroidectomy. The association with bone density needs further evaluation in larger studies.

Entities:  

Keywords:  Parathyroidectomy; Primary hyperparathyroidism; Surgery

Mesh:

Substances:

Year:  2017        PMID: 28853593      PMCID: PMC5697040          DOI: 10.1308/rcsann.2017.0092

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  22 in total

Review 1.  Primary hyperparathyroidism: pathophysiology and impact on bone.

Authors:  A Khan; J Bilezikian
Journal:  CMAJ       Date:  2000-07-25       Impact factor: 8.262

2.  Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop.

Authors:  John P Bilezikian; Aliya A Khan; John T Potts
Journal:  J Clin Endocrinol Metab       Date:  2009-02       Impact factor: 5.958

3.  Primary hyperparathyroidism: short-term changes in bone remodeling and bone mineral density following parathyroidectomy.

Authors:  P Christiansen; T Steiniche; K Brixen; I Hessov; F Melsen; L Heickendorff; L Mosekilde
Journal:  Bone       Date:  1999-08       Impact factor: 4.398

4.  Increased biochemical markers of bone formation and resorption in primary hyperparathyroidism with special reference to patients with mild disease.

Authors:  S Valdemarsson; B Lindergård; S Tibblin; A Bergenfelz
Journal:  J Intern Med       Date:  1998-02       Impact factor: 8.989

5.  Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients.

Authors:  P Christiansen; T Steiniche; K Brixen; I Hessov; F Melsen; P Charles; L Mosekilde
Journal:  Bone       Date:  1997-07       Impact factor: 4.398

Review 6.  Primary hyperparathyroidism: new concepts in clinical, densitometric and biochemical features.

Authors:  J P Bilezikian; M L Brandi; M Rubin; S J Silverberg
Journal:  J Intern Med       Date:  2005-01       Impact factor: 8.989

Review 7.  Skeletal effects of interventions in mild primary hyperparathyroidism: a meta-analysis.

Authors:  Shyam Sankaran; Greg Gamble; Mark Bolland; Ian R Reid; Andrew Grey
Journal:  J Clin Endocrinol Metab       Date:  2010-02-03       Impact factor: 5.958

8.  Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.

Authors:  Aliya A Khan; John P Bilezikian; Annie W C Kung; Mustafa M Ahmed; Sacha J Dubois; Andrew Y Y Ho; Debra Schussheim; Mishaela R Rubin; Atif M Shaikh; Shonni J Silverberg; Timothy I Standish; Zareen Syed; Zeba A Syed
Journal:  J Clin Endocrinol Metab       Date:  2004-07       Impact factor: 5.958

9.  Longitudinal changes in bone mineral density and bone turnover in postmenopausal women with primary hyperparathyroidism.

Authors:  C Y Guo; W E Thomas; A W al-Dehaimi; A M Assiri; R Eastell
Journal:  J Clin Endocrinol Metab       Date:  1996-10       Impact factor: 5.958

10.  Primary hyperparathyroidism. Changing clinical spectrum, prevalence of hypertension, and discriminant analysis of laboratory tests.

Authors:  F W Lafferty
Journal:  Arch Intern Med       Date:  1981-12
View more
  8 in total

Review 1.  Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism.

Authors:  Barbara C Silva; John P Bilezikian
Journal:  Rev Endocr Metab Disord       Date:  2020-11-16       Impact factor: 6.514

Review 2.  A Systematic Review of the Circadian Rhythm of Bone Markers in Blood.

Authors:  Sarah Seberg Diemar; Stig Søgaard Dahl; Anders Sode West; Sofie Amalie Simonsen; Helle Klingenberg Iversen; Niklas Rye Jørgensen
Journal:  Calcif Tissue Int       Date:  2022-03-19       Impact factor: 4.333

3.  CLINICAL FEATURES OF HYPERCALCEMIC CRISIS IN PRIMARY HYPERPARATHYROIDISM.

Authors:  U Turan; H Kilavuz; O Irkorucu
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Oct-Dec       Impact factor: 1.104

4.  Primary hyperparathyroidism: findings from the retrospective evaluation of cases over a 6-year period from a regional UK centre.

Authors:  Joseph M Pappachan; Mohamed Nabil Elnaggar; Ravinder Sodi; Kahtan Jbeili; Paul R Smith; Ian M Lahart
Journal:  Endocrine       Date:  2018-07-17       Impact factor: 3.633

5.  Preoperative imaging predicts change in bone mineral density after parathyroidectomy for primary hyperparathyroidism.

Authors:  Gabrielle K Steinl; Randy Yeh; Marcella D Walker; Catherine McManus; James A Lee; Jennifer H Kuo
Journal:  Bone       Date:  2021-02-02       Impact factor: 4.626

6.  The effect of parathyroidectomy compared to non-surgical surveillance on kidney function in primary hyperparathyroidism: a nationwide historic cohort study.

Authors:  Josephine Matzen; Lise Sofie Bislev; Tanja Sikjær; Lars Rolighed; Mette Friberg Hitz; Pia Eiken; Anne Pernille Hermann; Jens-Erik Beck Jensen; Bo Abrahamsen; Lars Rejnmark
Journal:  BMC Endocr Disord       Date:  2022-01-06       Impact factor: 2.763

7.  Bone Turnover Markers in Response to Ultrasound-Guided Microwave Ablation for Primary Hyperparathyroidism.

Authors:  Wenjing Ni; Yue Yuan; Xiaoqiu Chu; Guofang Chen; Xue Han; Jie Li; Xinping Wu; Jianhua Wang; Chao Liu; Shuhang Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-01       Impact factor: 5.555

8.  Management and outcomes of hyperparathyroidism: a case series from a single institution over two decades.

Authors:  Hassan Al-Thani; Moamena El-Matbouly; Maryam Al-Sulaiti; Mohammad Asim; Ahmad Majzoub; Abdelhakem Tabeb; Ayman El-Menyar
Journal:  Ther Clin Risk Manag       Date:  2018-07-31       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.